在头骨图像中异常的粉样β持续时间,Tau和神经退行
Henry Gilreath Stephenson1,2,3, Rebecca Langhough1,3,4, Erin Jonaitis1,3
1School of Medicine and Public Health, University of Wisconsin-Madison, Madison.
JAMA network open
|September 9, 2025
概括
粉样β (Aβ) 病理的持续时间,而不仅仅是它的存在,与神经退行相关,独立于tau病理. 较长的Aβ持续时间显示,与大脑缩有更强烈的关联.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 生物标志物 生物标志物
背景情况:
- 粉样β (Aβ) 病理和神经退行症的持续时间之间的关系,特别是关于病理的影响,仍然不清楚.
- 了解这种关系对于开发有效的阿尔茨海默病 (AD) 疗法至关重要.
研究的目的:
- 调查纵向大脑缩和粉样β定位子发射断层扫描 (PET) 阳性 (Aβ+) 之间的关联.
- 检查Aβ+估计持续时间对神经退行症的影响,同时控制tau阳性.
主要方法:
- 使用威斯康星州阿尔茨海默病预防登记处和威斯康星州阿尔茨海默病研究中心临床核心研究数据的纵向队列研究.
- 用匹兹堡化合物B (PiB) PET扫描和采样代局部近似 (SILA) 建模估计了β-粉样蛋白 (Aβ) 阳性及其持续时间.
- 使用MK-6240 PET评估tau阳性,并通过使用线性混合效应模型测量纵向MRI衍生的区域大脑缩来测量神经退行.
主要成果:
- 无论是Aβ+状态还是tau阳性,都与神经退行相关,尽管效果大小小.
- 估计的Aβ+病理的持续时间显示,与Aβ+状态单独相比,在多个区域与大脑缩有更广泛的关联,效果大小略大.
- 使用OASIS-3数据集的复制分析产生了类似的结果.
结论:
- 微妙的神经退行在Aβ病理的早期可以检测到.
- 这些发现表明,Aβ病理可能代表一种早期的病理状态,它启动了一连串导致神经退行症的过程.
- Aβ病理的持续时间是与神经退行症进展相关的重要因素,独立于tau.
相关概念视频
Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Amyloid Fibrils
11.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.5K
Amyloid Fibrils
6.2K
6.2K


